top of page
RECOVER (NOLVA)
RECOVER (NOLVA) is a popular and powerfully effective Selective Estrogen Receptor Modulator (SERM) that is often referred to as an anti-estrogen. However, while being an antagonist it is also an agonist as it will actually act as estrogen in certain parts of the body while acting as an anti-estrogen in other areas. As one of the oldest SERM’s on the market that is still regularly used medicinally, while RECOVER (NOLVA) is also used by anabolic steroid users it is not an anabolic steroid. This is an important note as some are often confused by its use in steroid cycles.
As an anti-estrogen, RECOVER (NOLVA) functions by binding to the estrogen receptors in the place of estrogen. This binding prevents the estrogen hormone from performing its action in certain parts of the body, which is precisely why it’s beneficial to breast cancer patients. Many forms of breast cancer actually feed off estrogen when it attaches to the receptors in the chest. By preventing the attachment in such receptors, this also protects anabolic steroid users from gynecomastia, which can be caused by anabolic steroids that aromatize such as Testosterone, Dianabol, and Nandrolone and Boldenone to a degree.

RECOVER (NOLVA)

$80.00Price

  • Dosage

    ALL REFERENCES OF USE ARE FOR RESEARCH SUBJECTS AND NOT HUMANS

    Concentration: 50mg/mL

     

    Volume: 30mL

    We suggest a dosage of 20-50mg everyday for 4 weeks. Each bottle is 30ml in volume and will last for around 30 days.

    Ingredients

    RECOVER: (Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine, Food-grade USP glycol, food-grade ethyl alcohol and essential oils.

    Medical Referances

    • Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ (Jul 2014). "Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update". Journal of Clinical Oncology. 32 (21): 2255–69.
    • Dueñas-Díez, edited by Antonio Cano Sanchez, Joaquim Calaf i Alsina, José-Luis (2006). Selective Estrogen Receptor Modulators a New Brand of Multitarget Drugs. Berlin, Heidelberg: Springer-Verlag Berlin Heidelberg. p. 52.
    • Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S (Sep 2007). "Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts". Cell. 130 (5): 811–23.

    Storage

    Cool and dark space like a cupboard or pantry.

bottom of page